Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. (February 2018)

• Record Type: Journal Article
• Authors: Beauval, Jean-Baptiste; Loriot, Yohann; Hennequin, Christophe; Rozet, François; Barthelemy, Philippe; Borchiellini, Delphine; Schlürmann Constans, Friederike; Gross, Emmanuel; Maillet, Denis; Pasticier, Gilles; Pignot, Géraldine; Timsit, Marc-Olivier; Vincendeau, Sébastien; Ploussard, Guillaume; Sargos, Paul
• Is Part Of: Critical reviews in oncology/hematology. Volume 122(2018)
• Page Start: 144
• Page End: 149
• Publication Date: 2018-02
• Subjects: Castration-resistant prostate cancer -- Local treatment -- Metastasis-directed treatment -- Prostatectomy -- Radiotherapy; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2017.12.012
• Languages: English
• ISSNs: 1040-8428

Abstract

Highlights: Local or regional targeted treatment has shown encouraging results in hormone sensitive metastatic PCa. This strategy was not addressed specifically in the non-metastatic or metastatic CRPC. Local or regional treatment could delay introduction of new systemic agent in CRPC and potentially limit induced resistance. This strategy could maintain the patient's quality of life. High-level evidence for oncologic benefit of this treatment modality is required. Abstract: Emerging evidence from population-based and retrospective series suggests a potential improvement of clinical outcomes in metastatic prostate cancer. Moreover, metastasis-directed treatment has shown encouraging results in this setting. There is an increasing interest in exploring the potential of local therapies in advanced prostate cancer, but this has rarely been specifically addressed in the castration-resistant state, whether non-metastatic or metastatic. A review of relevant articles was performed on the oncologic benefit of local treatment of the primary tumor or metastasis-targeted treatment in castration-resistant prostate cancer patients. The main goal of this strategy is to delay introduction of a new systemic agent to maintain quality of life and potentially to limit resistance. Further investigation is required to provide high-level evidence for the oncologic benefit of this treatment modality.